Numbers

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Thesis

Waaree trades at 29x TTM earnings because the market is pricing in a structural margin expansion story — from a 4% OPM commodity assembler in FY21 to a 25% OPM vertically integrated manufacturer in Q3 FY26 — with 49% revenue CAGR and negative working capital funding the growth. The single metric most likely to rerate or derate this stock is operating margin sustainability: if the 23-25% OPM proves structural (DCR mix, own cells, US production), fair value is well above the current price; if policy protection weakens or Chinese overcapacity bleeds through the tariff wall, margins revert to single digits and the stock collapses.

Quality Scorecard

Quality Score, Fair Value, Predictability, Altman Z, Piotroski F, and Beneish M data are not available for Waaree — the company listed in October 2024 and does not yet have sufficient history for these composite scores. What we can assess directly from fundamentals:

The financials tell a clean story: earnings convert to cash (CFO/NI consistently above 1.0x), the balance sheet is unlevered, and returns on capital are high. The missing ingredient is track record depth — Waaree has only been public for 18 months and its current margin profile is less than 3 years old.

Revenue & Earnings Power

Revenue grew 6.4x from FY20 to FY25 ($26M → $169M), but the real story is operating profit growing 26x ($1M → $32M). This is not a linear scale-up — it is a business whose unit economics transformed as backward integration, DCR mix, and export realization all improved simultaneously.

OPM tripled from 4-5% (FY20-22) to 19% (FY25), with the expansion accelerating as cell capacity ramped and DCR volumes grew. Net margin lagged slightly due to higher depreciation from capex, but still reached 13%.

The quarterly trajectory shows two inflection points: (1) the margin step-up from ~14-15% to 21-25% starting Q3 FY25 as own-cell integration kicked in, and (2) the revenue acceleration in H2 FY26 as module capacity crossed 1 GW/month. Q3 FY26 revenue of $84M was 119% higher YoY.

Cash Generation — Are the Earnings Real?

CFO has exceeded net income in every single year — the 5-year average CFO/NI ratio is 2.0x. This is unusual and structural: Waaree collects 5-15% advances on institutional orders and runs negative working capital (-87 days in FY25). The business generates cash before it delivers product.

FCF turned negative in FY25 ($-1M) as capex surged to $38M — driven by the 10 GW ingot/wafer plant, 15.4 GW cell expansion, US factory, and battery storage. This is a deliberate investment phase, not an earnings quality problem. Trailing 3-year FCF/NI (FY22-FY24) was 0.72x before the capex surge.

Capital Allocation

The pattern is clear: operating cash flow is being reinvested aggressively into capacity, with the gap funded by financing (IPO proceeds of ~$47M in FY25 and rising borrowings of $33M by H1 FY26). Dividends are token ($0.02/share in FY25 — a 0.06% yield). This is a growth-phase capital allocation profile — every dollar is going back into the business. The test comes in FY27-28 when the capex cycle matures and FCF should normalize.

Balance Sheet Health

The balance sheet deleveraged dramatically from D/E of 0.99x (FY21) to 0.13x (FY25) as equity expanded 27x through retained earnings and IPO proceeds, while borrowings grew modestly. However, H1 FY26 borrowings jumped to $33M (D/E ~0.26x) to fund the capex program. Still conservative for a manufacturing business of this scale, but the trend has reversed. Total assets have grown from $12M (FY20) to $277M (H1 FY26) — a 23x expansion in 5.5 years.

Valuation

Waaree listed in October 2024, so there is no multi-year valuation history to assess. The stock has traded in a $22-$41 range since listing.

At 30.8x TTM P/E, Waaree trades at a significant premium to the broader industrial sector but at a discount to Premier Energies (35.5x) and a steep discount to Tata Power (38.2x). Given 113% profit CAGR over 5 years and 100%+ YoY growth in recent quarters, the PEG ratio is well under 1.0x — suggesting the growth rate more than justifies the multiple. The risk is that this growth rate is decelerating faster than the market expects, particularly if US tariffs choke the export channel.

Peer Comparison

Waaree's closest pure-play comparator is Premier Energies, which commands a 15% P/E premium (35.5x vs 30.8x) on higher margins (27% vs 19% OPM) and superior ROCE (41% vs 35%). The premium is justified by Premier's cell-first strategy. But Waaree's 3.6x capacity advantage and $640M order book provide scale that Premier cannot match. The IPP/utility peers (Adani Green, NHPC, Tata Power) are not comparable — they are asset-heavy power generators, not manufacturers.

Fair Value & Scenario Analysis

Given the limited listed history, fair value estimates rely on earnings-based methods and analyst consensus.

Analyst consensus clusters around $38-$45 (Emkay, Motilal Oswal, Prabhudas Lilladher), implying 3-22% upside. The consensus assumes continued execution and manageable US tariff impact. The bear case is not remote — a 123% anti-dumping duty, if finalized in July 2026, would structurally impair the export thesis and force order book renegotiation on 65% of overseas orders.

Shareholding Evolution

The most striking shift: FII holdings surged from 0.7% (Mar 2025) to 7.1% (Mar 2026) — a 10x increase in institutional foreign ownership in one year. DII also doubled from 2.5% to 4.3%. Promoter holding remains stable at 64.2%. This institutional accumulation signals growing conviction from sophisticated capital, but also creates a potential overhang if the US tariff situation worsens.

What the Numbers Say

The numbers confirm that Waaree is a genuinely transformed business — not just a volume play, but a manufacturer with real margin expansion, exceptional cash conversion, and a balance sheet that can fund its ambitions — and contradict any residual narrative that this is a commodity assembler trading on hope, since every financial metric (CFO/NI, working capital, ROCE, margin trajectory) shows structural quality improvement. Watch the Q4 FY26 results (today, April 29) and the US anti-dumping final determination (July 2026) — together they will determine whether the 25% OPM and export revenue base survive into FY27, which is the entire ballgame for the valuation.